Develops evidence-backed therapeutics for severe rare and underserved diseases, advancing selected programs toward regulatory approval and patient access
Develops evidence-backed therapeutics for severe rare and underserved diseases, advancing selected programs toward regulatory approval and patient access. The company focuses on medicines with validated biology, prior clinical experience or established therapeutic use, and practical development paths.
The top three firms on F4's Biotech & Life Sciences investor list.